Box 1.

It is important to select the right patient for SGLT2 inhibitor therapy and avoid in others who may be at high risk of DKA.18 The following patients are likely to benefit most. Adults above 18 years with T2D and one or more of the following: established / high risk of cardiovascular diseasea chronic kidney disease with albuminuriaa history of heart failurea inadequate glycaemic control with need to minimise hypoglycaemia inadequate glycaemic control with need to minimise weight gain / encourage weight loss. Patients with a clear understanding of the risks associated with SGLT2 inhibitors and how to reduce those risks.

^aPlease refer to Table 1 for evidence of benefit for individual agents. DKA = diabetic ketoacidosis; SGLT2 = sodium glucose co-transporter 2.